Detalhe da pesquisa
1.
The BTLA-HVEM axis restricts CAR T cell efficacy in cancer.
Nat Immunol
; 25(6): 1020-1032, 2024 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-38831106
2.
Genetic and phenotypic attributes of splenic marginal zone lymphoma.
Blood
; 139(5): 732-747, 2022 02 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-34653238
3.
Modulation of the gut microbiota engages antigen cross-presentation to enhance antitumor effects of CAR T cell immunotherapy.
Mol Ther
; 31(3): 686-700, 2023 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36641624
4.
Safety and efficacy of a novel anti-CD19 chimeric antigen receptor T cell product targeting a membrane-proximal domain of CD19 with fast on- and off-rates against non-Hodgkin lymphoma: a first-in-human study.
Mol Cancer
; 22(1): 200, 2023 12 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-38066564
5.
CAR-T TREK through the lymphoma universe, to boldly go where no other therapy has gone before.
Br J Haematol
; 193(3): 449-465, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33222167
6.
Daratumumab for relapsed or refractory AL amyloidosis with high plasma cell burden.
Hematol Oncol
; 37(5): 595-600, 2019 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-31486522
7.
Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia.
Blood
; 126(16): 1921-4, 2015 Oct 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-26276669
8.
Bendamustine as Lymphodepletion for Brexucabtagene Autoleucel Therapy of Mantle Cell Lymphoma.
Transplant Cell Ther
; 2024 Mar 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-38494076
9.
Efficacy and safety of bendamustine for lymphodepletion before lisocabtagene maraleucel.
J Hematol Oncol
; 17(1): 19, 2024 Apr 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-38644469
10.
Directed evolution-based discovery of ligands for in vivo restimulation of CAR-T cells.
bioRxiv
; 2024 Apr 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-38659938
11.
CAR T-Cell Immunotherapy in Minority Patients with Lymphoma.
NEJM Evid
; 3(4): EVIDoa2300213, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38776868
12.
T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapy.
Nat Med
; 30(4): 984-989, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38266761
13.
Bendamustine lymphodepletion before axicabtagene ciloleucel is safe and associates with reduced inflammatory cytokines.
Blood Adv
; 8(3): 653-666, 2024 02 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-38113468
14.
Anti-PD-L1 monoclonal antibody for the management of chronic disseminated intravascular coagulation secondary to a urothelial carcinoma: a case report.
J Med Case Rep
; 16(1): 113, 2022 Mar 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-35307010
15.
Integration of Baseline Metabolic Parameters and Mutational Profiles Predicts Long-Term Response to First-Line Therapy in DLBCL Patients: A Post Hoc Analysis of the SAKK38/07 Study.
Cancers (Basel)
; 14(4)2022 Feb 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-35205765
16.
Modulation of BCL-2 in Both T Cells and Tumor Cells to Enhance Chimeric Antigen Receptor T-cell Immunotherapy against Cancer.
Cancer Discov
; 12(10): 2372-2391, 2022 10 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35904479
17.
Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy.
Nat Med
; 28(4): 713-723, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35288695
18.
Melphalan dose in myeloma patients ≥65 years of age undergoing high-dose therapy and autologous stem cell transplantation: a multicentric observational registry study.
Bone Marrow Transplant
; 54(7): 1029-1037, 2019 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-30390061
19.
Harnessing the Gut Microbiota to Potentiate the Efficacy of CAR T Cell Therapy.
Hemasphere
; 7(9): e950, 2023 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-37637993
20.
Author Correction: Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy.
Nat Med
; 29(11): 2954, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-36253610